The multidrug resistance in human leukemias Minireview

Neoplasma

Volumn 45, Issue 2, 1998, Pages 55-59

  Zubercova O ^a   Babusikova O ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Human leukemia; MDR

Indexed keywords

ANIMAL; EXPERIMENTAL LEUKEMIA; HUMAN; LEUKEMIA; MULTIDRUG RESISTANCE; REVIEW;

ANIMALS; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL;

EID: 0031614741     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Asou, N., NiSHiKAWA, K., SuzusHiMA, H., TAKATSUKI, K.: Expression of rnultidrug resistance 1 and correlation with clinical drug resistance in acute leukemia. Nippon Rinsho, 50, 1993,1400-1406.
2. BALL, L.M., HINCHLIFFE, S.A., BATARINGAYA, I, ENGLAND, K.E., JIANG, Y., HOWARD, C.V: Relationship between MDR 1 gene expression and AG-NOR pattern in childhood acute lymphoblastic leukemia. Meeting abstract. Cancer Res. Ther. Control, 4, 1994, 3-9.
3. BECK, J., HANDGRETINGER, R., KLINGEBIEL, T., DOPFER, R., SCHAICH, M., EHNINGER, G., NIETHAMMER, D., GEKELER, V: Expression of pkc isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia, 10, 1996, 426-433.
4. BECK, I, REGELE, B., BRUGGER, D., DIETL, J., SCHEPER, R.J., NIETHAMMER, D., BADER, R, HIRSCH, H.A., GEKELER, V: Expression of genes (MDR1, MRP, LRP, topoisomerases, PKC isozymes) possibly involved in drug resistance of ovarian carcinoma ascites cell aspirates. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37, 1996, A2100.
5. CACCIOLA, E., GUGLIELMO, P., STAGNO, F., CACCIOLA, R.R., IMPERA, S.: CD 34 expression in acute lymphoblastic leukemia. Leuk. Lymph.,;18, 1995,31-36.
6. CAIRO, M.S., KNOPPEL, E., GILLIAN, E.,FEUSNER, 1, GOLD, S., WELLS, R.: MDR expression of pédiatrie ALL and AML et diagnosis and relapse by PCR amplification: Rapid and sensitive detection. Meeting abstract. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 10, 1991, A 799.
7. CAO, Q.X., SULTZ, A., SCHEID, C., WICKRAMANAYAKE, P.D.: Quantitative analysis of MDR 1 gene expression in acute myeloid leukemia by reverse transcription polymerase chain reaction. Letter. Am. J. Hematol., 52, 1996, 3-9.
8. CROSTA, L., CANDILORO, V, MELI, M., TOLOMEO, M., RAUSA, L., DUSONCHET, L.: Lacidipine and josamycin: Two new multidrug resistance modulators. Anticancer Res., 14, 1994, 2685-2689.
9. DEL POETA, G., STASI, R., ARINICA, G., VENDITTI, A., Cox, M.C., BRUNO, A., BUCCISANO, F., MASI, M., TRIBALTO, M., AMADORI, S., PAPA, G.: Clinical relevance of P-glycoprotein expression in dc novo acute myeloid leukemia. Blood, 87, 1996, 1997-2004.
10. DIDIER, A., WENGER, J., LOOR, F.: Decreased uptake of cyclosporin A by P-glycoprotein expressing CEM leukemic cells and restoration of normal retention by pgp blockers. Anticancer Drugs, 6, 1995, 669-680.
11. FRICHE, E., NISSEN, N.T., BECK, W.T.: Expression of multidrug resistance-associated genes in sequential blood or marrow samples from AML patients. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37, 1996, 2124.
12. GOODMAN, S., GREER, J.P., STEIN, R.S., FLEXNER, J.M., WOLFF, S.N.: Drug resistance in leukemia and lymphoma: The clinical value of laboratory studies. Harwood Academic Publishers, 7, 1993,436.
13. GOTTESMAN, M.M., PASTAN, I.: Biochemistry of multidrug resistance mediated by the multi-drug transporter. Annu. Rev. Biochem., 62, 1993, 385-427.
14. GRUBER, A.: Clinical and experimental studies on human leukemias with special reference to multidrug resistance. Diss. Abstr. Int., 55, 1994,479.
15. GUERCI, A., MERLIN, J.L., MISSOUM, N., FELDMANN, L., MARCHAL, S., GUERCI, O.: Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult AML. Ann. Biol. Clin. (Paris), 54, 1996, 17-19.
16. HOGEWITSCH-BECKER, S., FALTZ, C, HOSSFELD, O.K.: The function of the P-glycoprotein pump decreases under deteriorating growth conditions: Implications for daunorubicin accumulation studies of leukemic cells. Meeting abstract. Anticancer Drugs, Suppl. 1, 5, 1994, 49.
17. KACZOROWSKI, S., OCHOCKA, M., KACZOROWSKA, M., ALEKSANDROWICZ, R., MATYSIAKL, M., KARWACKI, M.: Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: Correlation with clinical outcome. Leuk. Lymph., 20, 1995, 143-152.
18. KOBAYASHI, H., OHNUMA, T.: MDR1 ribozyme reverts multidrugresistant tumor cells back to drug-sensitive ones. Meeting abstract. 18th International Congress of Chemotherapy, 1995, June 27-July 2, Stockholm, Sweden, 380.
19. KOBAYASHI, H., DORAI, T.: Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 ribozyme. Cancer Res., 54, 1995, 1271-1275.
20. LAMY, T., DRENOU, B., GRULOIS, I., FARDEL, O., JACQUELINET, C., GOASGUEN, J., DAURIAC, C., AMIOT, L., BERNARD, M., FAUCHET, R. et al.: Multidrug resistance activity in AL determined by rhodamine 123 efflux assay. Leukemia, 9, 1995, 1549-1555.
21. LARSSON, R., FRIDBORO, H., CSOKA, K., BERGH, J., NYGREN, P.: Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. AnticancerRes., 12, 1995, 1581-1585.
22. Liso, V, SPECCHIA, G., PANSINI, N., MININNI, D., COLUCCI, A., MESTICE, A., VAIRA, A., MAGNO, M., DEBILLIS, G.: Expression of P-l 70 glycoprotein in adult acute leukemia. Meeting abstract. Haematologica, Suppl. 4, 76, 1996, 75.
23. LIST, A.F., GRIMM, M., GLINSMANN-UIBSON, B., FOLEY, N., DALTON, W.: Relative cytotoxicity and P-glycoprotein binding activity of idarubicin, daunorubicin and mitoxantrone in multidrug-resistant cell lines. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 34, 1995, A144.
24. LIST, A.F., SPIER, C., GREER, J., AZAR, C., MUTTER, I, WOLHF, S., SALMON, S., FUTSCHER, B., DALTON, W.: Biochemical modulation of anthracycline resistance in acute leukemia with cydosporin A. Meeting abstract. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 11, 1992, A865.
25. LIST, A.F., SPIER, C.: Multidrug resistance in acute leukemia: A conserved physiologic function. Leuk. Lymph., 8, 1993, 9-14.
26. LUAN, F.J., YANG, C.Z., SHAO, X.F.: Detection and analysis of multidrug resistance in 100 cases of acute leukemia. Chung Hua Chung Liu Tsa Chin, 16, 1994,360-363.
27. MARIE, J.P.: P-glycoprotein in adult hematopoetic malignancies. Hematol. Oncol. Clin. North. Am., 9, 1995,239-249.
28. MASLAK, P., HEGEWITSCH-BECKER, S., GODFREY, L., ANDREEFF, M.: Flow cytometric determination of multidrug resistant phenotype in AL. Cytometry, 17, 1995, 84-93.
29. MAYNADIE, M., LIYARD, G., SOLARY, E., ROIGNOT, CARLI, P.M.: Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: Comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines. Anticancer Res., 14 (6B), 1996, 2605-2609.
30. MAYNADIE, M., MOSKOVTSCHENKO, P., SOLARY, E., COUILLAULT, G., LIZARD, G., VOLOT, F.: MDR phenotype in acute lymphoblastic leukemia: A study of 128 cases. Meeting abstract. Hematology, 15 (5a), 1996, 1645.
31. MICHIELI, M., DAMIANI, D., MICHELUTTI, A., CANDONI, A., MASOLINI., P., SCAGGIANTE, B., QuADRIFOGLIO, F.,BACCARAN1, M.: P170 expression: A rapid method for predicting daunorubicin and idarubicin uptake and toxicity in leukemic cells. Meeting abstract. Anticancer Drugs, 5, 1995, 500-507.
32. MICHIELI, M., DAMIANI, D., MICHELUTTI, A., GRJMAZ, S., MELLI, C., ZAJA, F., BARILLARJ, G., SILVESTRI, F., FANIN, R., BACCARANI, M.: Restoring uptake and retention of daunorubicin and idarubicin in P170 related multidrug resistance cells by low concentration D-verapamil, cyclosporin A and SDZ PSC 833. Haematologica, 79, 1996, 534-557.
33. MINDERMAN, H., VANHOEFER, U., SLOVAK, M.L., WIZOSEK, C., MINDERMAN, M.D., RusTUM, Y.M.: DIOC2(3) is not substrate for multidrug resistance protein-mediated drug extrusion. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37, 1996, A2116.
34. MODRAK, D.E., DRAPER, P.M., LEVY, S.B.: Resistance in mel cell lines selected for resistance to adriamycin. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37,1996, A2184.
35. MULRONEY, C.M., GLUCK, S., Ho, A.D.: The use of photodynamic therapy in bone marrow purging. Semin. Oncol., 21, 1996, 24-27.
36. PITUCH-NOWOROLSKA, A., GAWLICKA, M., BALWIERZ, W.: The expression of multidrug resistance molecule in acute leukemia and lymphoma. Pol. J. Pathol., 45, 1995, 77-82.
37. PRINCIPE, P., SUBERVILLE, A.M., COULOMB, H., MARIE, J.P., BRAQUET, P.: Flow cytometric monitoring of anthracycline accumulation after antineoplast ether phospholipid treatment. Meeting abstract. Proc. Annu. Meet. Am. Assoc. Cancer Res., 34, 1994, A 1994.
38. RAGHU, G., PIERRE-JAROME, M., DORDAL, M.S., SIMONIAN, P., BAUER, K.D., WINTER, J.N.: P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. Int. J. Cancer, 53, 1996, 804-811.
39. ROWINSKY, E.K., ADJEI, A., DONEHOWER, R.C., GORE, S.D., JONES, R.J., BURKE, P.J., CHENG, Y.C., GROCOW, L.B., KAUFMANN, S.H.: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12, 1995, 2193-2203.
40. RUNDE, V, AUL, C., HOLLER, A., SCHNEIDER, W.: MDR in MDS and AL. Meeting abstract. In: International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, March 16, 1994, Amsterdam.
41. Russo, D., MICHELUTTI, A., MELLI, C., DAMIANI, D., MICHIELI, M.G., CANDONI, ZHOU, D.C., MARIE, J.P., ZITTOUN, R., BACCARANI, M.: MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia, 9, 1995, 513-516.
42. SALMON, S.E.,GROGAN,T., MILLER, T.P., LIST, A.F., TAYLOR, C.M., DALTON, W.S.: Reversal of MDR with chemosensitizers: Laboratory an clinical studies. Meeting abstract. Fourth International Congress on Anti-cancer Chemotherapy. February 2-5, 1995, Paris, France, 95.
43. SALMON, S.E., MILLER, T.P.: MDR and adjuvant therapy of cancer. Meeting abstract. 7th International Conference on the Adjuvant Therapy of Cancer, March 10-13, 1995,Tucson, Arizona, 25.
44. SCHRODER, J., ESTEBAN, M., MULLER, M.R., KASIMIR-BAUER, S., BAMBERGER, U., HECHEL, A., SEEBER, S., SCHEULEN, M.E.: Modulation of MDR by BIBW22BS in blasts of de novo or relapsed or persistent AML ex vivo. J. Cancer Res. Clin. Oncol., 722, 1996, 307-312.
45. SEDLAK, I, HUNÀKOVÂ, L., SULIKOVÂ, M., PAILINGEROVä, D., CHORVäTH, B.: Protein kinase inhibitor-induced alterations of drug uptake and surface antigen expression in human multidrug resistant, PGP and non-PGP promyelocytic leukemia (HL60) cells. Anticancer Res., 15, 1996, 1644.
46. SOLARY, E., CAILLOT, D., CHAUFFERT, B., CASASNOVAS, R.O., DUMAS, M., MAYNADIE, M., GUY, H.: Feasibility of using quinine, a potential MDR-reversing agent, in combination with mitoxanthrone and cytarabine for the treatment of AL. J. Clin. Oncol., 10, 1996, 1730-1736.
47. SOLARY, E., WITZ, B., CAILOTT, D., MOREAU, P., DESABLENS, B., CAHN, J.Y., SADOUN, A., PIGNON, B., BERTHOU, C., MALOISEL, F., GUYOTAT, D., CASSASUS, P., IFRAH, N., LAMY, Y, AUDHUY, B., COLOMBAT, P., HAROUSSEAU, J.L.: Combination of quinine as a potential reversing agent with mitoxantrone and cytoara-bine for the treatment of acute leukemias: A randomized multicenter study. Blood, 88, 1996, 1198-1205.
48. SOLARY, E., QUIQUANDON, I., MOREAU, P., WlTZ, B., CASASNOVAS, R.O., GENNE, P., CAHN, J.Y., SADOUN, A., PIGNON, B., BERTHOU, C. et al.: Phase II multicentric randomized study of quinine as a potential reversing agent in acute leukemias. Meeting abstract. Anticancer Drugs, Suppl. 1, 5, 1996,46-47.
49. STEPHENSON, J., CZEPULKOWSKI, B., HIRST, W., MUFTI, G.J.: Deletion of the acetylcholinesterase locus at 7Q22 associated with myelodysplastic syndromes and AML. Leuk. Res., 20,1996, 235-241.
50. TAFURJ, A., SOMMAGGIO, A., BURBA, L., ALBERGONI, M.P., PETRUCci, M.T., MASCOLO, M.G.,TESTi, A.M., BASSO, G.: Prognostic value of rhodamine efflux and MDR1/P170 expression in childhood acute leukemia. Leuk. Res., 19, 1995, 927-931.
51. TAKESHITA, A., SHINTO, K., OHNISHI, K., OHNO: New FC method for detection of minimally expressed MDR P-glycoprotein on normal and AL cells using biotinylated MRK16 and streptavidin-red 670 conjugal. Jpn. J. Cancer Res., 86,1995, 607-615.
52. THIBAUT, F., TSUORO, T.: Cellular localisation of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci., 84, 1987, 7735-7738.
53. URASAKI, Y., UEDA, T., YOSHIDA, A., FUKUSHIMA, T., TAKEUCHI, N., TSURUO, T., NAKAMURA, T.: Establishment of a daunorubicin-resistant cell line which shows MDR by multifactorial mechanisms. Anticancer Res., 16, 1996, 709-714.
54. UTZ, I., GELEKER, V, ISE, W., BECK, J., SPITALER, M., GRUNICKE. H., HOFMANN, J.: Protein kinase C isoenzymes, P53, accumulation of rhodamine 123, glutathione-s-transferase, topoisomerase FI and MRP in MDR cell lines. Anticancer Res., 16, 1996, 289-296.
55. VAN HOVE, L., VAN ACKER, K.: Complexity of MDR in human hematological malignancies as studies by FC and bioassays. Meeting abstract. J. Tumor Marker Oncol., 6, 1991,37-40.
56. YANG, R., YANG, C., HAD, Y: Study on the reversing effect of tripiperaquinine on human MDR leukemic cell line K562/ A02. Chung Hua Chung Liu Tsa Chih,17,1995, 340-342.
57. ZHOU, D.C., HOANG-NGOC, L., DELMER, A., FASSAUT, A.M., Russo, D., ZITTOUN, R., MARIE, J.P.: Expression of resistance genes in AL. Leuk. Lymph., Suppl. 1,13, 1995, 27-30.
58. ZHOUN, D.C., ZITTOUN, R., MARIE, J.P.: Homoharringtonine: An effective new natural product in cancer chemotherapy. Bull. Cancer (Paris), 82, 1996, 987-995.